<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(1)</volume><submitter>Hemmingsson J</submitter><funding>Vetenskapsrådet</funding><funding>University of Gothenburg</funding><funding>Stiftelsen Konung Gustaf V:s Jubileumsfond</funding><funding>Cancerfonden</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the treatment of disseminated disease, but its impact on the radiosensitive bone marrow needs to be evaluated. Using voxel-based skeletal dosimetry models in which active bone marrow is defined as regions containing stem cells and progenitor cells of the hematopoietic lineage, we generated S-values (absorbed dose per decay) for terbium-161 and evaluated its distribution-dependence in bone marrow cavities.&lt;h4>Methods&lt;/h4>S-values in the active bone marrow were calculated for terbium-161, lutetium-177, and yttrium-90 irradiation using two (male/female)</pubmed_abstract><journal>EJNMMI physics</journal><pagination>65</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9509518</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90.</pubmed_title><pmcid>PMC9509518</pmcid><pubmed_authors>Hemmingsson J</pubmed_authors><pubmed_authors>Svensson J</pubmed_authors><pubmed_authors>van der Meulen NP</pubmed_authors><pubmed_authors>Bernhardt P</pubmed_authors><pubmed_authors>Muller C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90.</name><description>&lt;h4>Background&lt;/h4>Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the treatment of disseminated disease, but its impact on the radiosensitive bone marrow needs to be evaluated. Using voxel-based skeletal dosimetry models in which active bone marrow is defined as regions containing stem cells and progenitor cells of the hematopoietic lineage, we generated S-values (absorbed dose per decay) for terbium-161 and evaluated its distribution-dependence in bone marrow cavities.&lt;h4>Methods&lt;/h4>S-values in the active bone marrow were calculated for terbium-161, lutetium-177, and yttrium-90 irradiation using two (male/female)</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-05-29T19:25:33.054Z</modification><creation>2025-05-29T19:25:33.054Z</creation></dates><accession>S-EPMC9509518</accession><cross_references><pubmed>36153386</pubmed><doi>10.1186/s40658-022-00495-7</doi></cross_references></HashMap>